Ischemic stroke is often caused by the occlusion of cerebral vessels, which subsequently affects its downstream branches, making the brain tissue lacking glucose and oxygen. Cerebral vessels have network that can compensate the blood flow; however, they are insufficient to rescue the entire ischemic area. Although stroke is the leading cause of long‐term disability and the second leading cause of death worldwide, there are only two Food and Drug Administration (FDA)‐ approved therapies;tissue plasminogen activator and thrombectomy. Neural stem cells (NSCs) have garnered significant interest as a multimodal therapy capable of producing neuroprotective and regenerative growth factors, In addition to serving as cell replacement for lost and damaged neural cell types. Another potentially attractive advantage of NSC therapy over conventional drug therapies is the ability of NSCs to continually respond to environmental cues and secrete appropriate quantities and type of signaling factors, therefore providing a tailored response to individual stroke injuries. Due to the significant potential of NSCs, these cells have progressed from testing in preclinical models to clinical trials for stroke with promising results.